Pechoux C, Chardonnet Y, Noël P
Unité de Morphologie Cellulaire et Tissulaire, Centre Léon Bérard, Lyon, France.
Anticancer Res. 1994 May-Jun;14(3B):1343-60.
The c-erb-B2 protein expression was evaluated by immunohistochemistry in two series of breast lesions. In a retrospective study on a series of 140 breast lesions, among 34 benign lesions, 16 showed an intense or moderate membrane reaction of tumoral cells; of 15 atypical lesions, 6 exhibited a membrane reaction and 34/60 in situ lesions expressed intensely or moderately c-erb-B2 oncoprotein. A prospective investigation was made on a series of 41 lesions from 25 patients, which were selected for their clinico-pathological features. All the samples were positive but the staining intensity was heterogenous. However, it was similar in the various lesions from the same patient. A strong signal was observed in 12 lesions from 7/25 patients, moderate in those of 13 patients and weak in 6 lesions from 5 patients. Taken together, our findings show that a large number of human breast lesions expressed c-erb-B2 oncoprotein, whether benign, atypical or in situ carcinomas. The intensity of the reaction may depend on the patients rather than on the aggressivity of the lesion, except for the infiltrating carcinomas. This suggests that c-erb-B2 oncoprotein in overexpressed at early stages of breast cancer lesions. Although c-erb-B2 oncoprotein is probably not a good marker for prognosis, it may be an indication for a future progression towards or recurrence.
采用免疫组织化学方法评估了两个系列乳腺病变中的c-erb-B2蛋白表达情况。在一项对140例乳腺病变的回顾性研究中,34例良性病变中,16例肿瘤细胞显示出强烈或中度的膜反应;15例非典型病变中,6例有膜反应,60例原位病变中有34例强烈或中度表达c-erb-B2癌蛋白。对来自25例患者的41例病变进行了前瞻性研究,这些病变因其临床病理特征而被选中。所有样本均呈阳性,但染色强度存在异质性。然而,同一患者的不同病变中的情况相似。在25例患者中的7例的12个病变中观察到强信号,13例患者的病变为中度信号,5例患者的6个病变为弱信号。综合来看,我们的研究结果表明,大量人类乳腺病变表达c-erb-B2癌蛋白,无论是良性、非典型还是原位癌。除浸润性癌外,反应强度可能取决于患者而非病变的侵袭性。这表明c-erb-B2癌蛋白在乳腺癌病变的早期阶段过度表达。虽然c-erb-B2癌蛋白可能不是一个良好的预后标志物,但它可能是未来进展或复发的一个指标。